Singapore markets close in 6 hours 28 minutes
Straits Times Index
3,274.33 -25.71 (-0.78%) Nikkei
38,399.26 -435.84 (-1.12%) Hang Seng
18,543.42 +64.05 (+0.35%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,740.58 -1,072.20 (-1.68%) CMC Crypto 200
1,299.52 -65.61 (-4.81%)
MCK Jan 2026 470.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:27AM EDT. Market open.
| Previous close | 132.78 |
| Open | 101.90 |
| Bid | 128.00 |
| Ask | 137.00 |
| Strike | 470.00 |
| Expiry date | 2026-01-16 |
| Day's range | 101.90 - 132.78 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
McKesson misses quarterly estimates as US pharmaceuticals segment weighs
McKesson Corp reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales in its U.S. pharmaceutical segment. The segment also sells branded and generic drugs, as well as over-the-counter products and vaccines. Sales in the segment rose 11.5% in the fourth quarter to $68.79 billion, but missed analysts' estimate of $71.65 billion, according to LSEG data.
ZacksMcKesson (MCK) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GuruFocus.comMcKesson Corp (MCK) Fiscal 2024 Earnings: Mixed Results Amidst Revenue Growth and Adjusted EPS ...
Insights into McKesson's Financial Performance and Future Outlook
© 2024 Yahoo. All rights reserved.